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        B cells diff  erentiate to antibody-secreting plasma 
cells (ASCs) in vivo in response to T cell  –  inde-
pendent (TI) antigens, generating extrafollicular 
ASCs that are short lived and secrete antibody 
of low affi   nity. Responses to T cell  –  dependent 
(TD) antigens proceed with diff  erent kinetics 
and in a specialized microenvironment, the 
germinal center, where T cells collaborate with 
their cognate B cells by providing signals that 
induce rapid division, isotype switching, and so-
matic hypermutation in the B cells. The ASCs 
that result from these interactions tend to be 
long lived and secrete antibodies of high affi   nity. 
The T cells signal to the B cell via surface CD40 
ligand (CD40L) and cytokines such as IL-4 and 
IL-5. In the mouse, IL-4 is both a survival factor 
for B cells and an inducer of isotype switching, 
primarily to IgG1 and IgE. In contrast, IL-5 acts 
to increase the likelihood of diff  erentiation of 
conventional B cells to ASCs (  1, 2  ) and supports 
B-1 cell proliferation, survival, and Ig produc-
tion (  3  –  6  ). 
  The intrinsic genetic program that drives the 
diff  erentiation of ASCs is becoming clear (  7  ). 
As a prerequisite, the B cell and germinal center 
programs, which are actively maintained in 
large part by Pax5 and Bcl6, respectively, must 
be extinguished. These transcription factors in-
hibit diff  erentiation by repressing genes that are 
required for ASC generation or function (  8  –  10  ). 
Critical among them is Blimp1, a transcrip-
tional repressor that is essential for the terminal 
diff  erentiation of ASCs ( 11  –  13  ). Once induced, 
Blimp1 neutralizes Pax5- and Bcl6-mediated 
repression, thus enabling the expression of the 
plasma cell  –  specifi  c gene program, in collab-
oration with other essential regulators such as 
IFN regulatory factor (IRF) 4 and Xbp1 (  14  –  16  ). 
Recent work has revealed that the initiation of 
plasma cell diff  erentiation is Blimp1 independent 
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  Mice lacking a functional gene for the Oct2 transcriptional activator display several devel-
opmental and functional defi  ciencies in the B lymphocyte lineage. These include defective 
B cell receptor (BCR) and Toll-like receptor 4 signaling, an absence of B-1 and marginal 
zone populations, and globally reduced levels of serum immunoglobulin (Ig) in naive and 
immunized animals. Oct2 was originally identifi  ed through its ability to bind to regulatory 
regions in the Ig loci, but genetic evidence has not supported an essential role for Oct2 in the 
expression of Ig genes. We describe a new Oct2-mediated role in B cells. Oct2 augments 
the ability of activated B cells to differentiate to antibody-secreting plasma cells (ASCs) 
under T cell  –  dependent conditions through direct regulation of the gene encoding the 
     chain of the interleukin (IL) 5 receptor. Ectopic expression of IL-5R     in oct2-defi  cient B 
cells largely restores their ability to differentiate to functional ASCs in vitro but does not 
correct other phenotypic defects in the mutants, such as the maturation and specialization 
of peripheral B cells, which must therefore rely on distinct Oct2 target genes. IL-5 aug-
ments ASC differentiation in vitro, and we show that IL-5 directly activates the plasma cell 
differentiation program by enhancing blimp1 expression. 410 OCT2 REQUIRED FOR IL-5  –  DRIVEN ASC DIFFERENTIATION | Emslie et al.
ASC diff  erentiation, as well as the signaling pathways that they 
engage, are important but poorly understood determinants of 
the humoral response. 
  Oct2, one of the fi  rst transcriptional activators recognized 
in B lymphocytes, was isolated as a nuclear factor that recog-
nizes a conserved motif in the promoters and enhancers of the 
Ig gene loci. Although early circumstantial fi  ndings suggested 
a role for Oct2 in the B cell  –  specifi  c expression of Ig genes, 
an essential role has not been substantiated by genetic studies 
(  21, 22  ). Instead, postnatal survival and the diff  erentiation and 
specialization of peripheral B cells depend on this factor (  23, 24  ). 
Nevertheless, serum antibody in naive oct2-null mice and 
their humoral immune responses are much diminished com-
pared with normal mice. The current study was designed to 
uncover factors contributing to this immunodefi  ciency. 
  As oct2       /       mice display several abnormalities within the 
B cell compartment, we chose to examine their capacity to 
diff  erentiate to ASCs under well-defi  ned in vitro conditions, 
where even small deviations from normal could be quanti-
tatively distinguished (  1  ). We found that oct2-null B cells 
and is accompanied by a decrease in Pax5 activity through 
a posttranslational mechanism that has not yet been ex-
plained (  17  ). 
  However, the extrinsic signals that initiate ASC diff  erenti-
ation are less clear. A strong signal through the BCR is thought 
to signal Bcl6 degradation and, thus, derepression of blimp1 (  18  ). 
Bacterial products such as LPS can drive TI ASC diff  erentia-
tion, whereas CD40L and T cell  –  derived cytokines signal TD 
ASC diff  erentiation, particularly IL-4, IL-5, and IL-21 in the 
mouse and IL-6 and IL-10 in humans. Interestingly, recent 
studies suggest that TD ASC diff  erentiation may require addi-
tional regulatory factors compared with TI ASC. For example, 
the coactivator Oct binding factor (OBF) 1, which regulates 
several aspects of mature B cell behavior, is selectively required 
for ASC diff  erentiation in vitro in response to T cell stimuli 
and in vivo in response to vaccination with a protein antigen 
(  19  ). In another study, the Stat3 protein, which is activated by 
many cytokines (including IL-6 and IL-10), was shown to be 
required for the generation of IgG-secreting ASCs (  20  ). These 
recent fi  ndings suggest that the nature of extrinsic regulators of 
    Figure 1.         IL-5  –  enhanced ASC differentiation requires Oct2.   (A) In vitro cultures of CFSE-labeled resting B cells (oct2   /    and  oct2     /     ) were stimulated 
as indicated for 4 d. ASCs were detected using anti-Syndecan1 staining, and isotype switching to IgG1 was also monitored. The percentage of ASCs or 
switched cells is indicated for each culture. (B, left) ELISPOT assay for Ig      secretion was performed on Syndecan1      cells sorted on day 4 from CD40L/IL-4 
cultures. 200 cells were plated (shaded bars, oct2   /   ; open bars, oct2      /     ). (right) Comparison, by ELISA, of the amount of Ig secreted during 5 h of culture 
by 6,000 syndcan1      oct2  /    and oct      /      ASCs. Values are means   ±   SD for triplicate cultures. (C) Percentage of Syndecan1      cells on day 4 in CD40L/IL-4 
cultures as a function of increasing IL-5 concentration (closed symbols, oct2   /   ; open symbols, oct2      /     ). (D) Percentage of isotype-switched (IgG1    )  cells 
on day 4 in CD40L/IL-4 cultures as a function of increasing IL-5 concentration and cell division. Values are means   ±   SD.     JEM VOL. 205, February 18, 2008 
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fetal liver has allowed the behavior of oct2-null lymphoid 
cells to be assessed. These studies highlighted the contribution 
that Oct2 makes to the diff  erentiation of specialized mature 
B cell subsets (unpublished data) (  24  ). Surprisingly, no evidence 
from studies on oct2 mutant mice supports the proposal that 
Oct2 regulates the transcription of Ig genes, either alone or in 
conjunction with its sometime partner, the coactivator OBF1/
OCA-B/Bob.1 (  25  ). Nevertheless, the serum of mice reconsti-
tuted with oct2       /       lymphocytes contains signifi  cantly lower 
levels of Ig of all isotypes than control reconstituted mice, 
whether naive or immunized (  23  –  25  ). 
  We therefore assessed the ability of oct2-null B cells to dif-
ferentiate to ASCs in vitro in response to CD40L and cytokines. 
These conditions were chosen for two reasons. First, we have 
made detailed, quantitative studies of the behavior of normal B 
cells under these conditions, measuring rates of cell division, 
isotype switching, and ASC diff  erentiation (  1  ), and we can 
therefore recognize deviations from normal responses. Second, 
oct2       /       B cells respond poorly to other polyclonal mitogens, 
such as LPS and BCR cross-linking antibodies (  23, 24, 26  ), so 
these activators could not be used. 
diff  erentiate normally to fully functional ASCs under conditions 
that mimic TD conditions (CD40L plus IL-4). Only when 
the diff  erentiation enhancing cytokine IL-5 was included did 
the mutant cells behave aberrantly. These studies led to the 
identifi  cation of the inducible chain of the IL-5 receptor, 
IL-5R     /CD125, as a B cell  –  specifi  c Oct2 target gene, and 
to a model whereby IL-5 signaling directly accelerates the 
ASC diff  erentiation program through increased expression of 
blimp1. Because Oct2 is required for several important re-
sponses in B cells, including BCR and Toll-like receptor 
(TLR) 4 signaling, several aspects of B cell diff  erentiation are 
disturbed in vivo in its absence. Its participation in TD ASC 
generation is unlikely to have been revealed without the use 
of the quantitative in vitro analyses used in this study. 
    RESULTS   
  oct2-defi  cient B cells differentiate normally to phenotypic 
ASCs in vitro but are insensitive to the enhancing effect 
of IL-5 
  Mice lacking the Oct2 transcription factor die perinatally, but 
reconstitution of immunodefi  cient Rag-1       /       mice with oct2       /       
    Figure 2.         T cell signals up-regulate IL-5R     and blimp1 expression and ASC differentiation.   (A)  IL-5R     (CD125) up-regulation requires simulta-
neous CD40 and IL-4 signals. (B) The IL-4 signal is transduced by Stat6. (C) Complete induction of CD125 depends on Oct2 but not OBF1. (D) Induction of 
CD125 from resting levels requires activation but is not dependent on cell division. CD125 is induced even in undivided cells in anti-CD40+IL-4 cultures 
of CFSE-labeled resting B cells (dotted line, cells treated with IL-4 only). (E) ASC (Syndecan1    ,  blimp/GFP    ) numbers are increased in response to IL-5 in 
in vitro cultures (CD40L/IL-4 plus IL-5, analyzed on day 4). (F) IL-5 treatment enhances blimp1 transcription directly. Real-time PCR measuring blimp1 
expression in B cells cultured in LPS (TI conditions) or anti-CD40+IL-4 (TD conditions) were as described in Materials and methods. CHX was added as 
indicated, and IL-5 was added to some cultures 1 h later. After a further 5 h, cells were harvested for RNA. Values are normalized to Hmbs, are means of 
triplicates   ±   SD, and are relative to unstimulated cells (for LPS) or     CD40-stimulated  cells.   412 OCT2 REQUIRED FOR IL-5  –  DRIVEN ASC DIFFERENTIATION | Emslie et al.
  Regulation of IL-5R     expression by T cell signals 
  Most resting B cells express the       chain but not the       chain 
of the IL-5 receptor and therefore do not respond to the 
  cytokine. Upon activation, IL-5R      is induced, and the cells 
become responsive (  Fig. 2 A  ) (  27, 28  ).   We therefore exam-
ined more closely the regulation of IL-5R      expression on 
WT and mutant B cells. Resting B cells were activated for 
2 d with anti-CD40 antibodies. This treatment did not signi-
fi  cantly elevate IL-5R      expression from resting cell levels 
(  Fig. 2 A  ), indicating that activation alone is not suffi   cient for 
IL-5R      induction. Weber et al. (  29  ) reported that IL-4 addi-
tion enhanced IL-5R      expression on LPS-treated B cells. 
We therefore looked for IL-5R      induction in response 
to IL-4. This cytokine alone did not induce IL-5R     , but 
the combination of      CD40 and IL-4 was a strong inducer 
(  Fig. 2 A  ), and this induction required Stat6, the primary sig-
nal transducer of the IL-4R (  Fig. 2 B  ). Oct2-defi  cient B cells 
failed to completely up-regulate IL-5R      under these condi-
tions, although expression of the receptor rose from resting 
cell levels (  Fig. 2 C  ). Thus, Oct2 contributes to, but does not 
entirely control, IL-5R      levels. Despite its role as an integra-
tor of CD40 and IL-4 signals in the context of germinal cen-
ter development, the coactivator OBF1 had no infl  uence on 
IL-5R      expression under these conditions (  Fig. 2 C  ). 
  We found that oct2-null B cells behave indistinguishably 
from WT B cells in CD40L+IL-4 cultures, undergoing iso-
type switching to IgG1 and diff  erentiating to Syndecan1  +   
ASCs in a cell division  –  linked manner (  Fig. 1 A  ).   Sorted 
Syndecan1  +   cells were ASCs, as determined by ELISPOT, 
and Oct2-defi  cient ASCs secreted at least as much Ig as did 
controls (  Fig. 1 B  ). 
  We previously demonstrated that when IL-5 was added to 
CD40L+IL-4 cultures, ASC diff  erentiation was enhanced. The 
ASCs generated in such cultures were rapidly dividing plasma-
blasts that were no longer able to switch isotypes (  1  ). This IL-5  –
  dependent enhancement can be seen in the control cultures of 
  Fig. 1 A   but not in oct2       /       B cell cultures (  Fig. 1 C  ). The sensi-
tivity of B cells to IL-5 is also refl  ected in the percentages of 
IgG1  +   cells in cultures with increasing IL-5 concentrations; at 
high concentrations, switched cells are less frequent in control 
cultures because a higher proportion of cells have become ASCs, 
which do not switch (  1  ). In oct2       /       cultures, IL-5 had no eff  ect 
on the proportion of switched cells, an indirect consequence of 
the lower frequency of ASC diff  erentiation (  Fig. 1 D  ). These 
data reveal both a new role for Oct2 in the cytokine-driven 
augmentation of ASC production and the absence of an essen-
tial role for Oct2 in the regulation of Ig production by pre-
formed ASCs. 
    Figure 3.         B cell  –  specifi  c, direct regulation of IL-5R     expression by Oct2.   (A) Anti-CD38 and IL-5 synergize to drive B cell proliferation (reference   66  ). 
Control B cells proliferated vigorously in response to      CD38 and IL-5 (shaded bars), but oct2      /      B cells (open bars) did not. Stimulation index is the ratio 
of cpm (measuring [  3  H]-thymidine incorporation) in stimulated cells relative to unstimulated cells. (B) Eosinophil colonies generated from embryonic day 
18 fetal liver in response to spleen-conditioned medium (SCM) or IL-5 were enumerated (left), and mean colony size was determined (right; shaded bars, 
Oct2   /   ; open bars, oct2      /     ). (C) Real-time PCR measurement of oct2, CD36, and IL-5R      expression in primary B cells, normalized to Hmbs, and relative to 
oct2      /      B cells. (D) Real-time PCR measurement of endogenous CD36 and IL-5R      expression in OM1A (oct2      /     ) B lymphoma cells and the same cells 
transduced with a retrovirus expressing an estradiol-inducible version of Oct2. Induction with estradiol (ES) in the presence or absence of CHX is described 
in Materials and methods. Values are means   ±   SD for triplicate samples.     JEM VOL. 205, February 18, 2008 
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     CD40+IL-4. The results indicated that IL-5R      is expressed 
even in undivided B cells (  Fig. 2 D  ). Thus, although IL-5 acts 
to enhance ASC generation, it is unlikely to contribute sig-
nifi  cantly to the cell division dependence of this diff  erentia-
tion step. 
  The observation that ASC diff  erentiation is cell division 
dependent (  1  ) prompted us to ask whether expression of the 
IL-5R      chain was also division linked. We purifi  ed resting 
B cells, labeled them with the cell division tracking dye CFSE, 
and stained for CD125 expression after 48 h in culture with 
    Figure 4.         Oct2 binds directly to the IL-5R     gene.   (A) Sequence of the 5      end of the mouse IL-5R      gene, indicating putative binding sites for Oct2, 
Stat5, and Stat6. IL-4 signals through Stat6, and IL-5 signals through Stat3 and 5 to up-regulate IL-5R      expression (reference   33  ). Vertical arrows mark 
the 5      ends of 5      RACE products (with bolded A residues at the preferred starts). Shaded boxes indicate putative TATA-binding factor and initiator recog-
nition sites. The underlined sequences indicate the ChIP probe fragments. Intronic sequences are in lower case; the coding sequence is bolded. The pro-
moter is represented by a diagram (bottom). (B) Quantitation of ChIP (two independent experiments) of endogenous Oct2 bound to the CD36 or IL-5R     
promoters in control WEHI231 or oct2-defi  cient OM1A lymphoma cells was performed using standard curves, and the WEHI231/control antibody sample 
was used as a reference. Values are means   ±   SD for triplicates. (C) EMSA showing a complex formed between a nuclear protein in LPS-activated B cells 
and double-stranded oligonucleotide probes matching the octamer 1 site of A. The presence of Oct2 in the complex is indicated by the supershift (**) 
caused by the addition of a monoclonal anti-Oct2 antibody. The octamer 2 site does not appear to bind signifi  cant amounts of Oct2. An oligo spanning 
the V  H  17.2.25 promoter is included as a positive control for Oct2 binding (V  H   octa; free, unbound probe). NS, nonspecifi   c  band.   414 OCT2 REQUIRED FOR IL-5  –  DRIVEN ASC DIFFERENTIATION | Emslie et al.
    Figure 5.         Selective rescue of ASC differentiation by an IL-5R     transgene.   (A) Increase in Syndecan1      cells generated from resting B cells in 
culture as a function of increasing IL-5 concentration (CD40L/IL-4 cultures were assessed at day 4). Each line shows the response of cells from an JEM VOL. 205, February 18, 2008 
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  As B cells required Oct2 to respond to IL-5 in all assays 
that we have performed, we assessed whether the IL-5R 
might require Oct2 for its expression. Although the IL-5R      
chain was not aff  ected in the mutants (not depicted), quanti-
tative PCR analysis showed that the IL-5R      chain was 
expressed at abnormally low levels in primary B cells from 
oct2       /       mice compared with control B cells (  Fig. 3 C  ). 
Indeed, the loss of Oct2 had an even more dramatic eff  ect on 
expression of this new putative target gene than was seen for 
the bona fi  de Oct2 target, CD36 (  Fig. 3 C  ) (  34, 35  ). 
  To begin to dissect the mechanism of action of Oct2 on 
the IL-5R      gene, we made use of OM1A, a cloned oct2       /       
B lymphoma cell line, and a cloned derivative that had been 
transduced with a retroviral construct expressing an Oct2  –
    estrogen receptor (ER) fusion protein (  36  ). In the absence of 
estradiol, Oct2-ER is cytoplasmic, and induction causes the 
Oct2-ER protein to moved quickly and quantitatively to the 
nucleus (unpublished data). The cells were induced with estra-
diol in the presence of CHX to ask whether Oct2 could directly 
activate transcription of the endogenous IL-5R      gene. Interest-
ingly, in contrast to the CD36 gene, estradiol  +  CHX modestly 
increased IL-5R      expression in the absence of Oct2-ER, 
implying that IL-5R      is normally repressed by a labile factor. 
Induction of Oct2 dramatically enhanced both CD36 and 
IL-5R      transcription in the absence of new protein synthesis 
(  Fig. 3 D  ), suggesting that Oct2 acts directly to activate the 
IL-5R      gene. 
  Oct2 binds to the IL-5R     gene promoter 
  Using 5      rapid amplifi  cation of complementary DNA (cDNA) 
ends (RACE), we found that the majority of IL-5R      transcripts 
in the spleen were initiated at or very near the A residue at 
position      4870 bp from the start of translation (or 166 bp up-
stream of the 5      end of the IL-5R      reference cDNA sequence, 
available from GenBank/EMBL/DDBJ under accession no. 
  NM_008370  ;   Fig. 4 A  ).   The adjacent sequences did not con-
tain a classical TATA box, but a 5-bp AT-rich sequence was 
found at approximately position      30 from the putative start of 
transcription. In their review of the features of eukaryotic pro-
moters, Smale and Kadonaga (  37  ) note that AT-rich sequences 
at approximately position      30 can profoundly infl  uence pro-
moter strength, even if they do not resemble the TATA con-
sensus. In addition, there is a fi  ve out of seven match to the 
consensus initiator sequence (  37  ) near the common 5      end of 
  IL-5 enhances blimp1/prdm1 expression 
  We next examined the molecular consequences of IL-5 treat-
ment on B cells. In these assays, the B cells were from a mouse 
expressing the GFP from the endogenous blimp1 promoter. 
Thus, all ASCs generated in vivo or in vitro express GFP (  30  ). 
Addition of IL-5 to CD40L+IL-4 cultures increased the 
number of cells expressing blimp1/GFP, and the GFP  +   cells 
were Syndecan1  +   ASCs (  Fig. 2 E   and not depicted). 
  To assess the ability of IL-5 to directly activate transcrip-
tion of the blimp1 gene, we prepared replicate cultures of WT 
B cells in LPS. 3 d later, cycloheximide (CHX) was added 
to both cultures at a concentration (50      M) that we deter-
mined would inhibit protein synthesis while preserving cell 
viability. 1 h later, IL-5 was added to one culture only, and 
cells were harvested 5 h after cytokine addition. Quantitative 
PCR analysis showed that LPS alone is a strong inducer of 
blimp1 expression, as expected (  Fig. 2 F  ). Addition of CHX did 
not infl  uence blimp1 messenger RNA levels, but the further 
addition of IL-5 enhanced blimp1 expression approximately 
fourfold over LPS alone (  Fig. 2 F  ). Blimp1 up-regulation was 
observed only in the IL-5  +   CHX-treated and not the IL-5  +   
DMSO-treated sample. Similar results were obtained in TD 
culture conditions, using anti-CD40+IL-4 to drive diff  eren-
tiation (  Fig. 2 F  ). These results suggest that the blimp1 gene 
is repressed by a labile repressor but that release from repres-
sion is alone insuffi   cient to activate the gene. The addition of 
IL-5 rapidly up-regulates blimp1 transcription in the absence 
of new protein synthesis, most likely through activation and 
nuclear transport of its cognate signal transducer, Stat5 (  31  ). 
There are two perfect consensus Stat5 binding sites in the 
blimp1 promoter, at positions      1325 and      931 relative to the 
start of transcription (  32  ). 
  Oct2 regulates the IL-5R     gene expression 
in B lymphocytes but not eosinophils 
  In addition to its eff  ects on diff  erentiation, IL-5 acts as a co-
activator for B cell proliferation when in combination with 
anti-CD38 (  33  ). This response is also absent in oct2       /       
B cells (  Fig. 3 A  ).   However, the proliferation of eosinophils, 
another IL-5  –  responsive cell type, was not dependent on Oct2. 
Oct2       /       fetal liver stem cells cultured in IL-5 gave rise to 
normal numbers of eosinophil colonies of normal size (  Fig. 3 B  ). 
Therefore, expression of the IL-5R is regulated diff  erently 
in B cells and eosinophils. 
independent reconstituted mouse of the indicated genotype. The percentages of Syndecan1      cells were made relative to the percentage generated without 
IL-5 for each sample, and the IL-5  –  dependent fold increase is displayed. This was done to enable comparison between experiments, as the mice in each 
cohort varied somewhat in their levels of B cell reconstitution, and the staining and analysis gates used on different days also varied slightly. The per-
centages of Syndecan1      cells in the non  –  IL-5 cultures ranged from 3 to 7.6% across the eight animals assessed. (B, left) Dot plot showing Syndecan1     
(GFP    ) ASCs (circled) in the spleens of mice reconstituted with oct2   /       or  oct2     /      B cells expressing the blimp1/gfp reporter allele. (right) Means of 
analyses of three animals (+SD) of each genotype (shaded bar, oct2   /      ; open bar, oct2      /     ). (C  –  G) Flow cytometric analysis of tissues of Rag1      /      mice 
reconstituted with the fetal liver from embryonic day 13 mice of the indicated genotypes (percentages are shown). (C) Splenocytes stained for B cell 
(B220) and T cell (thy-1) markers. (D) Splenic B cells stained with anti-IgM and anti-IgD as markers of maturity. (E) Spleens stained to identify MZ B cells 
(IgM  hi   and CD21  hi  ; circled). (F) Peritoneal lavage cells stained to detect the B-1 population (boxed). Equivalent results were obtained using B220 and 
Mac1/CD11b to identify B-1 cells (not depicted). (G) Serum Ig levels in naive mice (mean   ±   SD for four mice of each genotype; shaded bars, oct2   /  ; 
open bars, oct2      /    ).   
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the IL-5R      RACE products. These features suggest that the 
preferred transcriptional start site for the IL-5R      gene in sple-
nocytes (of which B lymphocytes are the major cell type) lies in 
this region. 
  A search of the upstream sequence of the IL-5R      gene 
using the ConSite transcription factor binding site search tool 
(  38  ) revealed two nonconsensus octamer motifs (  Fig. 4 A  ). 
Two methods were used to determine whether Oct2 is able 
to bind directly to these sites. First, chromatin immunoprecip-
itation (ChIP) was performed, using chromatin isolated from 
control WEHI231 or Oct2-defi  cient OM1A B lymphoma 
cell lines and a polyclonal anti-Oct2 antiserum. The results 
indicated that Oct2 bound specifi  cally to chromatin in the 
IL-5R      promoter in the vicinity of the two octamer motifs 
(5      ChIP) and to the CD36 promoter, a known Oct2 target 
gene (  Fig. 4 B  ). Two independent experiments are shown, 
and the relative enrichments (using WEHI231  +   preimmune 
serum as the reference sample) diff  er between experiments 
because the second experiment had a lower level of nonspe-
cifi  c immunoprecipitation overall. EMSA was used to learn 
whether one or both of the octamer motifs were bound by 
Oct2. IL-5R      octamer site 1 (the most 5     ) was able to bind 
to a nuclear protein, forming a complex that had the same 
mobility as an Oct2  –  consensus octamer DNA complex 
(V  H   octa) and that was specifi  cally supershifted by a mono-
clonal anti-Oct2 antibody (  Fig. 4 C  ). The more 3      IL-5R      
octamer site 2 did not exhibit specifi  c binding to Oct2. Col-
lectively, these data indicate that Oct2 binds directly to the 
promoter of the IL-5R      gene to activate its transcription 
specifi  cally in B cells. 
  Provision of an IL-5R     transgene selectively rescues ASC 
differentiation in oct2      /      B cells 
  We crossed the oct2 mutant mice to a transgenic mouse 
strain expressing the IL-5R      gene constitutively in B cells 
(  39  ) to determine whether enforced expression of IL-5R      
could rescue some aspects of the oct2 mutant phenotype. 
Because oct2       /       mice do not survive postnatally, all experi-
mental mice were generated using adoptive transfer of fetal 
liver stem cells into Rag1       /       recipients. The reconstituted 
mice were analyzed after at least 2 mo of reconstitution. 
We specifi  cally assessed the ability of the transgene to com-
plement the defective ASC diff  erentiation of oct2       /       B cells 
identifi  ed in vitro (  Fig. 1  ). Purifi  ed, resting splenic B cells 
from mice reconstituted with control, oct2-null or oct2-null/
IL-5R      transgenic fetal liver stem cells were cultured in 
CD40L+IL-4 in the presence or absence of IL-5. After 4 d, 
cells were harvested and stained for Syndecan1 expression, and 
antibody in culture supernatants was measured by ELISA. IL-5 
increased the proportion of Syndecan1  +   cells in the control 
but not the oct2-defi  cient cultures. The IL-5R      transgene 
largely restored the ability of oct2       /       cells to diff  erentiate in 
response to IL-5 in a concentration-dependent manner, gen-
erating a higher percentage of Syndecan1  +   cells and a cor-
responding increase in secreted Ig in the cultures (  Fig. 5 A   
and not depicted).   These reconstitution studies indicate that 
a primary role of Oct2 in these TD cultures is to activate 
the IL-5R      gene, enabling effi   cient diff  erentiation of ASCs. 
We also observed a lower proportion of Syndecan1  +   ASCs 
in the spleens and bone marrow of mice reconstituted with 
oct2       /       B cells expressing the blimp1/gfp reporter allele 
compared with controls (  Fig. 5 B   and not depicted). This may 
refl  ect, in part, a defi  ciency of ASCs that would have been 
generated in vivo during TD responses to environmental anti-
gens, mediated by IL-5 through Oct2 and IL-5R     . 
  We found that the IL-5R      transgene did not convinc-
ingly rescue any of the other defects of the B cell lineage of 
oct2 mutant mice in vivo. For example, the proportion of 
B cells in the spleen remained low (  Fig. 5 B  ), and there was 
an abnormally high percentage of immature cells in the spleen 
of oct2-null mice, whether or not they bore the IL-5R      
transgene (  Fig. 5 C  ). Similarly, the transgene failed to rescue 
the marginal zone (MZ) or B-1 cell populations of the oct2       /       
mice (  Fig. 5, D and E  ). It was regularly noted that the B-1 
compartment of control transgenic mice was larger than con-
trol nontransgenics, consistent with the reported activity of 
the transgene and the particular responsiveness of B-1 cells to 
IL-5 (  6  ). The failure of the transgene to complement these 
defects highlights the selective role that IL-5 and its receptor 
play during B cell development, and emphasizes the fact that 
Oct2 regulates other genes important for normal B lympho-
cyte development and function, such as those mediating BCR 
signaling (  23  ). 
    DISCUSSION   
  Recently, many groups have worked to elucidate the intrinsic 
factors that are required for the differentiation of antigen-
activated B cells into ASCs (  7  ). These studies have identifi  ed 
essential transcriptional regulators, such as Blimp1, Bach2, Bcl6, 
IRF4, Xbp-1, and Pax5, whose activities orchestrate the tran-
sition from the mature B cell and germinal center genetic 
programs to one dedicated to high level Ig synthesis and secre-
tion. Less clear are the modes of action of extrinsic signals, as 
well as their associated downstream signaling pathways, in 
initiating or enhancing this important transition. In this 
study, we consider the T cell  –  derived cytokine IL-5 as one 
such extrinsic signal. 
  In the mouse B cell lineage, IL-5 seems to serve primar-
ily as an enhancer of antibody. It supports cells of the B-1 
cell lineage, which constitutively express IL-5R      (  27, 40  ). 
These cells are the source of most   “  natural  ”   Ig in the serum 
and are poised to diff  erentiate very rapidly to ASCs upon 
activation (  41  ). Resting follicular B cells are unresponsive to 
IL-5. We show that two T cell signals, CD40L and IL-4, 
strongly synergize to condition splenic B cells to become 
IL-5 sensitive. This dramatic synergy would ensure that only 
those B cells activated in the context of T cell help could be 
accelerated toward ASC diff  erentiation by IL-5. In follicular 
B cells, IL-5 has a clear and specifi  c activity in enhancing 
ASC diff  erentiation from follicular B cells (  Fig. 1  ) (  1  ). Fi-
nally, IL-5 has been shown to improve the survival of BM-
derived plasma cells (  42  ). We show that Oct2 is required for JEM VOL. 205, February 18, 2008 
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  It is not yet known whether Oct2 contributes to human 
TD ASCs through IL-5, or another cytokine, in an analogous 
way to the mouse. There is less evidence for a role of IL-5 on 
human B lymphocytes, although actions of IL-5 on human 
B cells have been reported (  45, 46  ). Instead, IL-6 and/or IL-10 
induce ASC diff  erentiation of CD40L-activated human B cells 
in vitro (  47  –  49  ). Both IL-6 and IL-10 signal through Stat3, as 
can IL-5 (  50  ). 
  Our in vitro evidence (  Fig. 2 E   and not depicted) sug-
gesting that IL-5 alone is unable to up-regulate blimp1 ex-
pression in mouse B cells indicates that the blimp1 gene is 
insulated against untimely induction. Here, a short pulse of 
IL-5 was only able to stimulate blimp1 expression after 3 d of 
culture. At earlier time points (24  –  48 h of culture), blimp1 ex-
pression was not infl  uenced by IL-5 addition (unpublished data). 
These observations accord with those reported by Horikawa 
et al. (  2  ) showing that IL-5 induces blimp1 in CD38-acti-
vated B cells slowly (over several days). These observations, 
the requirement for several cell divisions before ASC diff  er-
entiation occurs in vitro (  1  ), and the positive eff  ect that an 
inhibitor of protein synthesis had on blimp1 expression (  Fig. 2  ) 
are all consistent with the obligate loss of a blimp1 repressor 
over the fi  rst hours and days of activation. Once the repres-
sion is released, the blimp1 gene of a plasma cell precursor 
B cells to be able to eff  ectively   “  read  ”   this T cell signal. 
Oct2 binds directly to the promoter of the IL-5R      gene and 
increases its transcription in splenic B cells. We have dem-
onstrated a dependence on Oct2 during ASC diff  erentiation 
in vitro in response to IL-5 stimulation, as well as a specifi  c 
improvement of diff  erentiation effi   ciency when IL-5R      was 
provided to Oct2-defi  cent B cells as a transgene. 
  Overexpression of IL-5 has been shown to signifi  cantly in-
crease antibody levels in vivo, predominantly from an expanded 
population of B-1 cells (  40  ). Conversely, IL-5R       –  defi  cient or 
IL-5  –  depleted mice showed impaired B-1 cell development 
and reduced serum IgM, IgG3 and mucosal IgA (  6, 39, 43  ). 
The IL-5R      transgene used in this study supported increased 
percentages of peritoneal B-1 cells in control mice but no 
rescue of this population in the oct2       /       mutants (  Fig. 5 E  ). 
Furthermore, it was not possible to rescue the serum antibody 
defect in oct2-defi  cient animals by reconstitution with this 
single Oct2 target gene (  Fig. 5 F  ), probably because serum Ig 
mainly comprises IgM from B-1 cells, and TD ASCs represent 
a minority of both cells and Ig in vivo. The contribution of 
other Oct2 target genes to antibody responses, through BCR 
signaling, B-1 and MZ B cell populations, and TLR4 signaling 
(important for both TI and TD humoral responses) (  44  ), prob-
ably overshadows the eff  ect of IL-5 in vivo. 
    Figure 6.         A model for the specifi  c impact of extrinsic signals on the intrinsic regulation of TD ASC differentiation.   The phenotype and behav-
ior of germinal center B cells is maintained through the repressive activities of Bcl6, Bach2, and Pax5. Upon immune activation, antigen can signal Bcl6 
degradation, and T cells, through CD40, can magnify this effect by activating IRF4, a repressor of Bcl6 transcription (reference   59  ). T cell  –  derived cyto-
kines, such as IL-4 and IL-5 (see Results), combine to activate blimp1 transcription. Pax5 protein activity is down-modulated by an unknown mechanism 
(reference   17  ). Once Blimp1 and IRF4 reach suffi  ciently high levels (and Bcl6, Pax5, and Bach2 levels have been reduced), the ASC program is reinforced by 
unopposed repression of Bcl6, Pax5, and Bach2 by the plasma cell determinants IRF4 and Blimp1.     418 OCT2 REQUIRED FOR IL-5  –  DRIVEN ASC DIFFERENTIATION | Emslie et al.
physiological roles of tissue-restricted gene regulators such as 
Oct2 and OBF1. 
  MATERIALS AND METHODS 
  Cell preparation and culture.     All mice used in the study were on a 
C57BL/6 genetic background, including the blimp1-GFP reporter (  30  ) 
and IL-5R      transgenic mice (  39  ). All animal studies were approved by the 
Animal Ethics Committee of the Royal Melbourne Hospital Research Foun-
dation. Splenic B cells were prepared as previously described (  19  ), using anti-
CD45R/B220  –  coupled magnetic beads (Miltenyi Biotec). For CFSE labeling 
experiments, Percoll gradients were included to enrich for resting cells, as 
previously described (  1  ). Soluble CD40L and recombinant IL-4 and IL-5, 
purifi  ed from baculovirus-infected Sf9 cells (both used at 1,000 U/ml unless 
otherwise noted in the fi  gures), and LPS (from 10   μ  g/ml   Escherichia coli   0111:
B4; Sigma-Aldrich) were used as previously described (  1, 19  ). Anti-CD38 
(NIM-R5) and anti-CD40 (FGK-4.5) were purifi  ed from hybridomas pro-
vided by M. Howard (ChemoCentryx Inc., Mountain View, CA) and A. 
Rolink (University of Basel, Basel, Switzerland), and were used at 10   μ  g/ml. 
[  3  H]Thymidine incorporation was used as previously described (  23  ) to mea-
sure proliferation in vitro. 
  Embryonic day 18 fetal liver cells were cultured at 25,000 cells per milliliter 
in 1-ml cultures of Dulbecco  ’  s modifi  ed Eagle  ’  s medium with 20% fetal calf se-
rum and 0.3% agar. The reagents used to stimulate eosinophil colony formation 
were 0.1 ml of pokeweed mitogen  –  stimulated spleen-conditioned medium 
containing GM-CSF and IL-3, or 10 ng/ml IL-5, as a specifi  c stimulus for 
eosinophil colony formation. Cultures were scored after 7 d. Cell counts   ±   SD 
were made on individual colonies in the stained cultures. 
  For the experiments in   Fig. 2 F  , the sensitivity of LPS-activated B cells to 
CHX was determined. B cells were cultured in LPS for 3 d, and then 
for 6 h with increasing concentrations of CHX, after which viability (using 
propidium iodide exclusion) and protein translational activity (using incorpo-
ration of 1   μ  Ci per well of [  35  S]-Express protein labeling mix; Perkin Elmer) 
were measured. At 50   μ  M CHX, translation was completely inhibited, but cell 
viability was equivalent to control cultures treated with DMSO only (not de-
picted). B cells were cultured for 3 d with the stimuli shown in   Fig. 2 F  , CHX 
or DMSO were added, and IL-5 was added to selected cultures 1 h later. Cells 
were harvested for RNA from all cultures 5 h after cytokine addition. 
  The oct2       /       B lymphoma cell line OM1A (  36  ) was infected with a retro-
viral vector (pMX-pie) (  62  ) expressing GFP and oct2 fused to the hormone 
binding domain of the human ER from a single transcript. Puromycin resistant 
clones were selected for high GFP expression, and the      -estradiol  –  inducible 
nuclear translocation of the oct2-ER fusion protein was confi  rmed by sub-
cellular fractionation and Western blotting (unpublished data). For the induction 
experiments in   Fig. 3 D  , a clone of OM1A  –  oct2-ER was cultured with 50   μ  M 
CHX (or DMSO as a vehicle control). 1 h later, IL-5 was added to the indi-
cated cultures, and the cells were harvested for RNA after a further 5 h. 
  Flow cytometry.     Anti-Syndecan1 (281-2), anti-CD125 (T21), and anti-
B220 (RA3-6B2; all PE conjugated), and anti  –  thy-1.2 (30-H12), anti-IgM 
(R6-60.2), anti-IgD (11-26c.2a), and anti-CD23 (B3B4; all FITC conju-
gated) were purchased from BD Biosciences. Anti-CD21 was purifi  ed from 
a hybridoma supplied by K. Inoue (Osaka University Medical School, 
Osaka, Japan) and biotinylated. A. Strasser (Walter and Eliza Hall Institute, 
Melbourne, Australia) purifi  ed the NimR-5 (anti-CD38) antibody. CFSE 
labeling was performed as previously described (  1  ). 
  ELISPOT and ELISA.     In   Fig. 1 B  , 200 sorted Syndecan1  +   cells from day 4 
of a culture (CD40L+IL-4) of resting B cells were plated for ELISPOT assay, 
performed essentially as previously described (  1  ) using anti-Ig       –  coupled 
horseradish peroxidase as the developing reagent. For the ELISA assay, 6,000 
sorted Syndecan1  +   cells were plated in medium without stimuli, and the 
culture supernatants were harvested 6 h later. Measurement of Ig     , IgM, and 
IgG1 levels in culture supernatants, or Ig levels in serum, was performed as 
previously described (  63  ). 
would become responsive to the positive infl  uence of IL-5 
signaling. Strong candidates for the blimp1 repressors are 
Bcl6 (  8  ) and Bach2, which have been shown to bind directly 
to the blimp1 gene (  51, 67  ), and Pax5 (  9, 52, 53  ). Indeed, 
Horikawa et al. showed that bcl6 messenger RNA levels de-
clined within hours of IL-5 addition in their culture system (  2  ), 
and Kallies et al. showed that a reduction of Pax5 activity 
precedes blimp1 induction (  17  ). 
  In vivo, signals that derepress the blimp1 gene are likely 
to come from T cells and their products and through the 
BCR, as has been proposed by Niu et al. (  18  ). In one model, 
Bcl6 competes for binding on the blimp1 gene with the tran-
scriptional activator Stat3, with which it shares a consensus 
DNA binding motif (  54  ). A strong BCR signal leads to deg-
radation of Bcl6, vacating the DNA binding site in favor of 
Stat3, which is activated in response to IL-6 and other cyto-
kines. It is intriguing to note that Stat3 binds to the same 
consensus DNA binding motif as Stat5 (  55  ). Stat5 is a major 
transducer of signals from the IL-5R (  56  ). Thus, Bcl6 and 
Stat5 may also compete as negative and positive regulators of 
blimp1 expression. 
  Recent work has highlighted the importance of the com-
bined infl  uences of blimp1 and IRF4 during ASC diff  eren-
tiation (  17, 57, 58  ). Thus a model for TD ASC diff  erentiation 
in vivo (  Fig. 6  ) may incorporate the combined eff  ects of 
antigen receptor signaling (to relieve Bcl6 repression) and 
T cell signals: a CD40 signal to up-regulate IRF4 expression 
through the canonical NF-     B pathway and to further reduce 
Bcl6 expression (  59  ), and cytokines such as IL-5, which boost 
the expression of the blimp1 gene (  Fig. 2 F  ).   Once blimp1 
and IRF4 levels reach a critical threshold, a mutual reinforce-
ment has been proposed (  57, 58  ) that drives the ASC diff  er-
entiation program forward. 
  Both Oct2 and OBF1 have been shown by genetic mod-
els to be entirely dispensable for Ig gene expression in B cells 
and plasma cells. However, these two transcription factors are 
required for some of the main   “  sensing  ”   functions of B cells 
(e.g., Oct2 for LPS sensing through TLR4, and Oct2 and 
OBF1 for antigen signaling through the BCR and for cyto-
kine responses; see Results; unpublished data). As a result, 
many aspects of peripheral B cell behavior are faulty in the 
mice. OBF1       /       mice lack germinal centers and MZ B cells, 
and display a reduced mature B cell pool (  60, 61  ). Oct2-null 
mice also lack MZ B cells and most mature B cells, as well as 
the B-1 cell population (unpublished data) (  24  ). In the face of 
these many defects, it was diffi   cult to discern their specifi  c 
roles in ASC diff  erentiation. Using quantitative in vitro analy-
ses, novel modes of action for Oct2 and OBF1 have been dis-
covered, whereby each is required for a diff  erent aspect of TD 
terminal ASC diff  erentiation (see Results) (  19  ). The infl  uence 
of each factor on serum Ig is indirect and molecularly distinct, 
with OBF1 required for TD but not TI ASC diff  erentiation, 
and with Oct2 enabling the IL-5 response. The latter defect 
was molecularly characterized and specifi  cally corrected in the 
studies described in this paper. Such approaches strongly 
complement global gene expression studies to determine the JEM VOL. 205, February 18, 2008 
ARTICLE
419
oligonucleotides were labeled using [  32  P]dATP and Klenow DNA polymerase. 
Oligo sequences were as follows: IL-5R      octa-1, (forward) 5     -GGG  GTCA-
CATATCAGATATCTTGCATATCAGATATC-3      and (reverse) 5     -TTT-
GATATCTGATATGCAAGATATCTGATATGTGACCCC-3     ; IL-5R      
octa-2, (forward) 5     -CTCTGCTAGTCACTCAGCATGAAAATCCTCA-
GACT-3      and (reverse) 5     -TTTAGTCTGAGGATTTTCATGCTGAGT-
GACTAGCAGAG-3     ; and V  H   octa, (forward) 5     -CCTTGCCTCATGA-
GTATGCAAATCATGTGCGACTG-3      and (reverse) 5     -TTTCAGTC-
GCACATGATTTGCATACTCATGAGGCAAGG-3     . 
  Fetal liver reconstitutions.     Day 13 embryos were recovered, fetal livers 
were dissected, and cell suspensions were prepared. After genotyping, the 
cells of interest were transplanted into irradiated (300 Rad) Rag1       /       recipients, 
as previously described (  23  ), at a ratio of three recipients per donor liver. Reconsti-
tution was monitored by the appearance of mature lymphocytes in peripheral 
blood, and only stably reconstituted mice were included in the analyses 
presented in this paper. 
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ing to the manufacturer  ’  s instructions. The expression data were analyzed on 
a sequence detection system (ABI Prism 7900HT; Applied Biosystems), using 
relative quantifi  cation of gene expression. Expression was normalized using 
hydroxymethylbilane synthase (Hmbs) as a housekeeping gene. For the ChIP 
assays, the absolute quantifi  cation using standard curves was used to measure 
the products for PCR reactions. 
  Primers used for cDNA amplifi  cation were as follows: Hmbs, (forward) 
5     -GACCTGGTTGTTCACTCCCTGAAG-3      and (reverse) 5     -GACAA-
CAGCATCACAAGGGTTTTC-3     ; CD36, (forward) 5     -CAGCTCATA-
CATTGCTGTTTATGCATG-3      and (reverse) 5     -GGTACAATCACAG-
TGTTTTCTACGTGG-3     ; oct2, (forward) 5    -GCATCGAGACGAATGTC-
CGCTTCG-3      and (reverse) 5     -GTAGCTGGTCGGCTTTCCCGGGCT-3     ; 
IL-5R     , (forward) 5     -CAGTGGGAGAAACCACTTTCTGCC-3      and 
(reverse) 5     -GAGATGCCATTCTACCAAGGACTTC-3     ; and blimp1, the 
QuantiTect Primer Assay for Mm_Prdm1 (QIAGEN). 
  5     RACE.     The transcriptional start site for the mouse IL-5R      gene was 
mapped using a RACE cDNA amplifi  cation kit (SMART; BD Biosciences). 
Gene-specifi  c nested primers were 5      IL-5R       –  1 (5     -GCGTTAGCTCT-
GTCTCTGCTGATAACAGGGC-3     ) and 5      IL-5R       –  2 (5     -CTGCAT-
ACCGGGACCTGTCCAGTGAGCTTC-3     ). A single prominent product 
was generated from the 5      RACE PCR reaction, which was purifi  ed from 
an agarose gel, and cloned. At least one dozen clones were bidirectionally 
sequenced to ensure that microheterogeneities in sequence length were 
not overlooked. 
  ChIP.     ChIP was performed essentially as described by Ramirez-Carrozzi 
et al. (  64  ). Specifi  cally, chromatin from 1.2   ×   10  8   WEHI231 and OM1A 
cells was cross-linked using 1% formaldehyde for 10 min at room tempera-
ture. The cells were collected after two cold PBS washes, resuspended in 10 
ml of cell lysis buff  er (5 mM Pipes [pH 7], 85 mM KCl, 0.5% NP-40), and 
lysed for 10 min on ice. Nuclei were resuspended in 1 ml of nuclei lysis buff  er 
(50 mM Tris-HCl [pH 7], 10 mM EDTA, 1% SDS) and sonicated with 30-s 
pulses using a sonifi  er (Branson) until the DNA was reduced in size to     500 bp. 
The purifi  ed chromatin (350   μ  g) was diluted twofold with ChIP dilution 
buff  er (16.7 mM Tris-HCl [pH 7], 167 mM NaCl, 1.2 mM EDTA, 0.01% 
SDS, 1.1% Triton X-100) supplemented with 100  μ  g/ml of sonicated herring 
sperm DNA and protease inhibitors. After preclearing with 100   μ  l of protein 
G  –  sepharose for 2 h at 4  °  C, the diluted chromatin was immunoprecipitated 
overnight at 4  °  C using 5   μ  l of rabbit anti-Oct2 antiserum (  26  ) or preimmune 
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(forward) 5     -GGCTAAAGCTCGCAGAGTTCTCAGATTG-3      and 
(reverse) 5     -GCGTTAGCTCTGTCTCTGCTGATAACAGGGC-3     . 
  EMSA.     Nuclear extracts were prepared (  65  ) and EMSA was performed 
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